ABSTRACT
Soft-tissue sarcoma is a rare tumor in children and is considerably rarer still in the newborn period. Their behavior is, for the most part, benign with malignant varieties accounting for no more than 2" of all sarcomatous lesions in childhood. Although multifactorial elements are felt to contribute to the development of malignant tumors, the majority have a genetic component. Single gene mutations and more complex constitutional chromosomal anomalies favor the development of neonatal neoplasms. In general, treatment is tailored to the individual patient but should, if possible, be with a curative intent while limiting the toxicity of therapy and avoiding morbidity or mutilating surgery. All patients need histological diagnosis either by open, tru-cut, or fine-needle aspiration cytology (FNAC). The sensitivity of the young patient to the potential side effects of chemotherapy is well documented and indicates the need for treatment in a pediatric oncology center.
